Please wait





Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Checkbox not checked   Rule 13d-1(b)
Checkbox checked   Rule 13d-1(c)
Checkbox not checked   Rule 13d-1(d)




schemaVersion:


SCHEDULE 13G




Comment for Type of Reporting Person:  (1) The percent calculation is based on 54,165,030 shares of Common Stock outstanding as of August 3, 2026, as disclosed in Eikon Therapeutics, Inc.'s Quarterly Report on Form 10-Q for the fiscal quarter ended June 30, 2026, filed with the U.S. Securities and Exchange Commission (the "SEC") on August 13, 2026 (the "Form 10-Q").


SCHEDULE 13G




Comment for Type of Reporting Person:  (1) Platinum Falcon B 2018 RSC Limited ("Platinum Falcon") is the direct owner of 1,147,138 of the shares of Common Stock reported herein. Platinum Falcon is a wholly owned subsidiary of Abu Dhabi Investment Authority. Pursuant to the rules and regulations of the SEC, Abu Dhabi Investment Authority may be deemed to be the beneficial owner of the shares of Common Stock directly held by Platinum Falcon. (2) The percent calculation is based on 54,165,030 shares of Common Stock outstanding as of August 3, 2026, as disclosed in Eikon Therapeutics, Inc.'s Form 10-Q.


SCHEDULE 13G



 
Abu Dhabi Investment Authority
 
Signature:/s/ Saif Almashghouni
Name/Title:Saif Almashghouni / Authorized Signatory
Date:10/02/2026
 
Signature:/s/ Ahmed AlNeyadi
Name/Title:Ahmed AlNeyadi / Authorized Signatory
Date:10/02/2026
 
Platinum Falcon B 2018 RSC Limited
 
Signature:/s/ Saif Almashghouni
Name/Title:Saif Almashghouni / Authorized Signatory
Date:10/02/2026
 
Signature:/s/ Ahmed AlNeyadi
Name/Title:Ahmed AlNeyadi / Authorized Signatory
Date:10/02/2026